Dabomb Protein Biotech Corporation (6578) AI Stock Analysis

Dabomb Protein Biotech Corporation

(TPEx:6578)

Select Model

Rating:47Neutral

Price Target:TWD 16.50▼(-2.94% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by persistent operating losses, declining revenue, and negative free cash flow. Strong debt reduction and a generally neutral technical setup provide partial support, but the negative P/E and weak profitability keep the overall score low.

Positive Factors

Protein Biotechnology CapabilitiesProtein expression, purification, and technical R&D services give Dabomb a defined role in the biopharma and research-tools supply chain. These capabilities can support recurring customer relationships and exposure to life-science applications over the medium term.

Negative Factors

Revenue ContractionA multi-year revenue decline, including a sharp contraction in 2025, signals weakening commercial momentum and reduces operating scale. Persistent top-line pressure can make it harder to absorb fixed costs, fund development, and establish durable earnings power in the coming quarters.

Dabomb Protein Biotech Corporation (6578) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.21B
Dividend Yield: 2.37%
Average Volume (3M): 56.84K
Price to Earnings (P/E): -51.7
Beta (1Y): 0.06
Revenue Growth: 21.50%
EPS Growth: -5.51%
Country: TW
Employees: 46
Sector: General
Sector Strength: 55
Industry: Packaged Foods

Dabomb Protein Biotech Corporation Business Overview & Revenue Model

Company Description

DaBomb Protein Biotech Corp. is a specialized biotechnology enterprise primarily dedicated to developing and commercializing antibiotic replacements for the animal health industry. Its extensive product range includes plant-based proteins such as DaB...

Dabomb Protein Biotech Corporation Financial Statement Overview

Summary

Persistent revenue declines, substantial operating and net losses, and negative free cash flow outweigh the strong balance sheet and sharply reduced debt.

Income Statement

18Very Negative

Balance Sheet

82Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	339.44M	309.33M	337.82M	384.41M	433.63M	470.63M
Gross Profit	56.07M	69.03M	68.73M	46.43M	19.33M	21.65M
EBITDA	35.71M	-22.25M	34.98M	-26.00M	-15.49M	-40.80M
Net Income	-41.91M	-69.34M	11.64M	-57.02M	-44.66M	-62.45M
Balance Sheet
Total Assets	1.12B	1.10B	1.32B	1.40B	1.28B	1.34B
Cash, Cash Equivalents and Short-Term Investments	168.72M	160.63M	304.98M	429.45M	232.01M	266.87M
Total Debt	68.49M	74.21M	168.53M	418.00M	496.04M	618.30M
Total Liabilities	111.38M	106.48M	225.96M	443.83M	552.88M	662.24M
Stockholders Equity	1.01B	989.28M	1.09B	958.06M	727.20M	674.24M
Cash Flow
Free Cash Flow	25.34M	-21.04M	17.23M	-12.37M	-449.00K	-376.35M
Operating Cash Flow	40.36M	16.65M	47.55M	6.51M	19.71M	-44.25M
Investing Cash Flow	-16.32M	-14.42M	-31.48M	-31.89M	12.96M	-382.75M
Financing Cash Flow	-97.52M	-122.84M	-139.75M	208.85M	-34.15M	356.71M

Dabomb Protein Biotech Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6578 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6846	55Neutral	TWD 1.33B	12.56	―	8.05%	-3.09%	-27.22%
TW:4133	48Neutral	TWD 1.20B	27.03	―	0.56%	-4.19%	―
TW:6578	47Neutral	TWD 1.21B	-51.66	―	2.37%	21.50%	-5.51%

* General Sector Average

Performance Comparison

TW:6578 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6578	Dabomb Protein Biotech Corporation	17.00	-2.65	-13.49%
TW:4133	Abnova Taiwan Corp.	20.00	-3.47	-14.79%
TW:6827	MegaPro Biomedical Co., Ltd.	15.30	-0.20	-1.29%
TW:6846	Greenyn Biotechnology Co., Ltd.	49.00	-23.75	-32.65%
TW:6886	Far East Bio-Tec. Co., Ltd.	36.70	-2.64	-6.71%
TW:7814	Horien Biochemical Technology Co., Ltd.	27.30	-11.35	-29.37%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Dabomb Protein Biotech Corporation AI Stock Analysis